Brief: Redhill Biopharma Reports Further Analysis Of Phase 2/3 Data With Oral Opaganib In Moderately Severe Covid-19 Patients

Redhill Biopharma

04/10/2021 13:00

Oct 4 (Reuters) - RedHill Biopharma:
    * REDHILL BIOPHARMA REPORTS FURTHER ANALYSIS OF PHASE 2/3
DATA
WITH ORAL OPAGANIB IN MODERATELY SEVERE COVID-19 PATIENTS
    * REDHILL BIOPHARMA - OPAGANIB TREATMENT RESULTED IN A
STATISTICALLY SIGNIFICANT 62% REDUCTION IN MORTALITY
    * REDHILL BIOPHARMA - MEDIAN FOUR DAYS EARLIER HOSPITAL
DISCHARGE
FOR OPAGANIB-TREATED PATIENTS VERSUS. PLACEBO
    * REDHILL BIOPHARMA - DATA SHOWS 21% STATISTICALLY
SIGNIFICANT
EFFICACY BENEFIT WITH OPAGANIB IN REACHING ROOM AIR BY DAY 14
    * REDHILL BIOPHARMA - MODERATELY SEVERE GROUP COMPRISED 53%
OF
STUDY PARTICIPANTS REQUIRING A FRACTION OF INSPIRED OXYGEN UP TO
60% AT BASELINE
    * REDHILL BIOPHARMA - 77% OF OPAGANIB-TREATED PATIENTS
REACHED
ROOM AIR BY DAY 14 VERSUS. 63.5% FOR PLACEBO – AN EFFICACY
BENEFIT OF 21% WITH OPAGANIB
    * REDHILL BIOPHARMA - ADVERSE EVENTS WERE BALANCED BETWEEN
OPAGANIB AND PLACEBO GROUPS, SUGGESTING GOOD SAFETY, WITH NO NEW
SAFETY SIGNALS EMERGING


 ((Reuters.Briefs@thomsonreuters.com;))